Aura Biosciences Inc.
AURA | NASDAQ
$6.37
+$0.01 (+0.16%)
Sep 22, 2026, 2:45 PM ET · Market open
Company Profile
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Key Executives
| Name | Position |
|---|---|
| Natalie C. Holles | President, CEO & Director |
| Conor Kilroy | Chief Legal Officer & Secretary |
| Julie Person | Chief People Officer |
| Mark Plavsic | Chief Technology Officer |
| Susan Abu-Absi | Chief Operating Officer |
| Alex Dasalla | Head of Investor Relations & Corporate Communications |
| Amy Elazzouzi | Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer |
| Anthony Daniels | Vice President & Therapeutic Area of Head Ocular Oncology |
| Anthony S. Gibney | Chief Financial & Business Officer |
| Erica Kratz | Chief Regulatory & Quality Officer |
| Jill Hopkins | Chief Medical Officer & President of Research and Development |
| Joe McQuaid | VP & Therapeutic Area Head of Urologic Oncology |
| Patrick Nealon | Senior Vice President of Clinical Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | S-8 | Filing |
| Aug 20, 2026 | EFFECT | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 12, 2026 | 3 | Filing |
Aura Biosciences Inc.
| Country | United States |
| IPO Date | Oct 28, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 113 |
| CEO | Natalie C. Holles |
Contact Details
85 Bolton Street Boston,
Massachusetts 02135 United States
Stock Details
| Ticker Symbol | AURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501796 |
| CUSIP Number | 05153U107 |
| ISIN Number | US05153U1079 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove AURA